Cargando…

Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson’s Disease

Background: Mitochondrial dysfunction has been identified as a pathophysiological hallmark of disease onset and progression in patients with Parkinsonian disorders. Besides the overall emergence of gene therapies in treating these patients, this highly relevant molecular concept has not yet been def...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prasuhn, Jannik, Brüggemann, Norbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623067/ https://www.ncbi.nlm.nih.gov/pubmed/34828446 http://dx.doi.org/10.3390/genes12111840

Ejemplares similares

Genotype-driven therapeutic developments in Parkinson’s disease
por: Prasuhn, Jannik, et al.
Publicado: (2021)

Neuroinflammation and Mitochondrial Dysfunction in Parkinson’s Disease: Connecting Neuroimaging with Pathophysiology
por: Pizarro-Galleguillos, Benjamin Matís, et al.
Publicado: (2023)

Iron- and Neuromelanin-Weighted Neuroimaging to Study Mitochondrial Dysfunction in Patients with Parkinson’s Disease
por: Pizarro-Galleguillos, Benjamin Matis, et al.
Publicado: (2022)

Relationship between brain iron deposition and mitochondrial dysfunction in idiopathic Parkinson’s disease
por: Prasuhn, Jannik, et al.
Publicado: (2022)

A machine learning-based classification approach on Parkinson’s disease diffusion tensor imaging datasets
por: Prasuhn, Jannik, et al.
Publicado: (2020)

The Use of Vitamin K2 in Patients With Parkinson's Disease and Mitochondrial Dysfunction (PD-K2): A Theranostic Pilot Study in a Placebo-Controlled Parallel Group Design
por: Prasuhn, Jannik, et al.
Publicado: (2021)

Neuroimaging Methods to Map In Vivo Changes of OXPHOS and Oxidative Stress in Neurodegenerative Disorders
por: Prasuhn, Jannik, et al.
Publicado: (2022)

Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities
por: Prasuhn, Jannik, et al.
Publicado: (2021)

Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign?
por: Prasuhn, Jannik, et al.
Publicado: (2021)

Applicability of optical coherence tomography angiography (OCTA) imaging in Parkinson’s disease
por: Lauermann, Jost L., et al.
Publicado: (2021)

Mitochondrial dysfunction in Parkinson’s disease
por: Hu, Qingsong, et al.
Publicado: (2016)

Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
por: Henrich, Martin T., et al.
Publicado: (2023)

Mitochondrial Dysfunction in Parkinson's Disease
por: Keane, P. C., et al.
Publicado: (2011)

Mitochondrial Dysfunction in Parkinson's Disease
por: Moon, Hyo Eun, et al.
Publicado: (2015)

An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial
por: Prasuhn, Jannik, et al.
Publicado: (2019)

Depressive symptoms in Parkinson’s disease are insufficiently but more often treated than in other chronic conditions
por: Usnich, Tatiana, et al.
Publicado: (2023)

Mitochondrial Dysfunction in Parkinson’s Disease: Focus on Mitochondrial DNA
por: Buneeva, Olga, et al.
Publicado: (2020)

Transient Generalized Chorea in Influenza A Encephalopathy
por: Prasuhn, Jannik, et al.
Publicado: (2018)

The genetic architecture of mitochondrial dysfunction in Parkinson’s disease
por: Larsen, S. B., et al.
Publicado: (2018)

Mitochondrial Dysfunction in Parkinson’s Disease—Cause or Consequence?
por: Chen, Chun, et al.
Publicado: (2019)

Mitochondrial dysfunction-targeting therapeutics of natural products in Parkinson’s disease
por: He, Ting, et al.
Publicado: (2023)

Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease
por: Hoekstra, Jake G, et al.
Publicado: (2011)

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches
por: Huang, Yue, et al.
Publicado: (2022)

Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection
por: Mounsey, Ross B., et al.
Publicado: (2010)

Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives
por: Park, Jin-Sung, et al.
Publicado: (2018)

Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson’s Disease
por: Tryphena, Kamatham Pushpa, et al.
Publicado: (2023)

Mitochondrial dysfunction in kidney injury, inflammation, and disease: potential therapeutic approaches
por: Bhatia, Divya, et al.
Publicado: (2020)

The epigenetic mechanisms involved in mitochondrial dysfunction: Implication for Parkinson’s disease
por: Chen, Zixuan, et al.
Publicado: (2021)

Therapies for Genetic Forms of Parkinson’s Disease: Systematic Literature Review
por: Over, Laura, et al.
Publicado: (2021)

Dietary Macronutrient Management to Treat Mitochondrial Dysfunction in Parkinson’s Disease
por: Bajracharya, Rijan, et al.
Publicado: (2019)

Gastrointestinal Dysfunction in Parkinson’s Disease: Current and Potential Therapeutics
por: Han, Myat Noe, et al.
Publicado: (2022)

Mitochondrial Dysfunction and Therapeutic Perspectives in Cardiovascular Diseases
por: Liu, Yu, et al.
Publicado: (2022)

Mitochondrial Dysfunction in Cardiac Diseases and Therapeutic Strategies
por: Huang, Yafei, et al.
Publicado: (2023)

Neurobiology and clinical features of impulse control failure in Parkinson’s disease
por: Béreau, Matthieu, et al.
Publicado: (2019)

From the Gut to the Brain and Back: Therapeutic Approaches for the Treatment of Network Dysfunction in Parkinson's Disease
por: Paolone, Giovanna
Publicado: (2020)

Genome-Edited, TH-expressing Neuroblastoma Cells as a Disease Model for Dopamine-Related Disorders: A Proof-of-Concept Study on DJ-1-deficient Parkinsonism
por: Prasuhn, Jannik, et al.
Publicado: (2018)

Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease: The Emerging Role of VDAC
por: Risiglione, Pierpaolo, et al.
Publicado: (2021)

Increased Subcortical Sodium Levels in Patients with Progressive Supranuclear Palsy
por: Prasuhn, Jannik, et al.
Publicado: (2022)

Mitochondrial Dysfunction and Parkinson’s Disease—Near-Infrared Photobiomodulation as a Potential Therapeutic Strategy
por: Foo, Aaron Song Chuan, et al.
Publicado: (2020)

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications
por: Zheng, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ba8qlt7e527dauk7rk0c595pqk